EP Magazine: Researchers, industry, and patient advocacy groups are driving efforts to facilitate early diagnosis and improve babies' long-term outlook. Commentary by Catherine Nester, BSN, Inozyme's VP of Physician and Patient Strategies.
STAT: The ever-lower cost is helping to drive fast-moving changes in sequencing. Health systems are preparing to test programs that could lead to the use of whole-genome screening in millions of newborns.
PHARMAVOICE: Newborn screening is gaining prominence across the biopharma and healthcare industries amid efforts to detect and treat disease as early as possible.